TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies

Benzinga Logo Benzinga By Vandana Singh
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies

GSK and Ionis Pharmaceuticals announced positive Phase 3 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B. The B-Well 1 and B-Well 2 studies, involving over 1,800 patients, met their primary endpoint with statistically significant functional cure rates. If approved, bepirovirsen could become the first finite, six-month therapeutic option for CHB. Regulatory submissions are planned for Q1 2026.

Insights
GSK   positive

GSK's partnered drug met primary endpoints in large Phase 3 studies with clinically meaningful results, supporting potential regulatory approval and market opportunity for a novel hepatitis B treatment.